|
Hormone receptor status (n=46)
| | | |
|
Positive
|
6
|
22
|
0.368
|
|
Negative
|
2
|
16
| |
|
Response to neoadjuvant chemotherapy (n=37)
| | | |
|
pCR (grade 3)
|
1
|
19
|
0.019
|
|
No pCR (grade 0–2)
|
6
|
11
| |
|
Relapse after surgery (n=42)
| | | |
|
Not occurred
|
3
|
27
|
0.018
|
|
Occurred
|
5
|
7
| |
|
Wild-type HER2 mRNA (n=41)
| | | |
|
< 400
|
5
|
18
|
0.035
|
|
≥ 400
|
0
|
18
| |
|
ΔHER2 mRNA (n=41)
| | | |
|
< 4.5
|
4
|
15
|
0.107
|
|
≥ 4.5
|
1
|
21
| |
|
Percentages of ΔHER2 mRNA (n=41)
| | | |
|
< 2.4%
|
3
|
32
|
0.087
|
|
≥ 2.4%
|
2
|
4
| |
|
PI3KCA (exons 9 and 20) (n=46)
| | | |
|
Wild-type
|
5
|
35
|
0.024
|
|
Mutated
|
3
|
3
| |
|
PI3KCA (exons 9 and 20) (n=46)
| | | |
|
Wild-type + Normal + Loss + UPD
|
2
|
29
|
0.005
|
|
Mutated + Gain
|
6
|
9
| |
|
PTEN (n=46)
| | | |
|
Normal + Gain + UPD
|
5
|
36
|
0.008
|
|
Loss
|
3
|
2
| |
|
INPP4B (n=46)
| | | |
|
Normal + Gain + UPD
|
6
|
36
|
0.072
|
|
Loss
|
2
|
2
| |
|
PI3KCA , PTEN, INPP4B (n=46)
| | | |
|
No aberrations*
|
1
|
24
|
0.009
|
|
Aberrations**
|
7
|
14
| |
|
DEK (n=46)
| | | |
|
Normal
|
3
|
27
|
0.07
|
|
Gain
|
5
|
11
| |
|
FGFR1 (n=46)
| | | |
|
Normal + Loss + UPD
|
4
|
27
|
0.248
|
|
Gain
|
4
|
11
| |
|
CCND1 (n=46)
| | | |
|
Normal + Loss
|
4
|
21
|
0.786
|
|
Gain
|
4
|
17
| |
|
FOXA1 (n=46)
| | | |
|
Normal + UPD
|
4
|
29
|
0.133
|
|
Gain
|
4
|
9
| |
|
CDH3 (n=46)
| | | |
|
Normal + Loss + UPD
|
6
|
35
|
0.158
|
|
Gain
|
2
|
3
| |
|
BIRC5 (n=46)
| | | |
|
Normal + Loss + UPD
|
6
|
23
|
0.441
|
|
Gain
|
2
|
15
| |
|
MYBL2 (n=46)
| | | |
|
Normal + Loss
|
4
|
28
|
0.186
|
|
Gain
|
4
|
10
| |
|
AIB1 (n=46)
| | | |
|
Normal + Loss
|
5
|
28
|
0.523
|
|
Gain
|
3
|
10
| |
